Patent ID: 7482321

Claim:
An extended GLP-1 peptide comprising an amino acid sequence of the formula: (SEQ ID NO: 1) Xaa 7 -Xaa 8 -Glu-Gly-Thr-Xaa 12 -Thr-Ser-Asp-Xaa 16 -Ser- Xaa 18 -Xaa 19 -Xaa 20 -Glu-Xaa 22 -Gln-Ala-Xaa 25 -Lys- Xaa 27 -Phe-Ile-Xaa 30 -Trp-Leu-Xaa 33 -Xaa 34 -Gly-Xaa 36 - Xaa 37 -Xaa 38 -Xaa 39 -Xaa 40 -Xaa 41 -Xaa 42 -Xaa 43 -Xaa 44 - Xaa 45 -Xaa 46 -Xaa 47 -Xaa 48 -Xaa 49 -Xaa 50 Formula 1 wherein: Xaa 7 is: L-histidine; Xaa 8 is: Gly, or Val; Xaa 12 is: Phe; Xaa 16 is: Val, Trp, Ile, Leu, Phe, or Tyr; Xaa 18 is: Ser; Xaa 19 is: Tyr; Xaa 20 is: Leu, Phe, Tyr, or Trp; Xaa 22 is: Glu; Xaa 25 is: Ala, Val, Ile, or Leu; Xaa 27 is: Glu, Ile, or Ala; Xaa 30 is: Ala or Glu Xaa 33 is: Val or Ile; Xaa 34 is: Lys, Asp, Arg, or Glu; Xaa 36 is: Gly, Pro, or Arg; Xaa 37 is: Gly, Pro, or Ser; Xaa 38 is: Ser, Pro, or His; Xaa 39 is: Ser, Arg, Thr, Trp, or Lys; Xaa 40 is: Ser or Gly; Xaa 41 is: Ala, Asp, Arg, Glu, Lys, or Gly; Xaa 42 is: Pro, or Ala; Xaa 43 is: Pro, or Ala; Xaa 44 is: Pro, Ala, Arg, Lys, or His; Xaa 45 is: Ser, His, Pro, Lys, Arg, or Gly; Xaa 46 is: His, Ser, Arg, Lys, Pro, or Gly; Xaa 47 is: His, Ser, Arg, Lys, NH 2 or is absent; Xaa 48 is: Gly, His, NH 2 or is absent; Xaa 49 is: Pro, His, NH 2 or is absent; and Xaa 50 is: Ser, His, Ser-NH 2 , His-NH 2 or is absent; and wherein the first 31 amino acids of the peptide do not differ from GLP-1 (7-37) at more than 6 of the corresponding variable positions and wherein the extended GLP-1 peptide has insulinotropic activity.